Adverse drug reactions in South African patients being treated for XDR-TB

K. Shean, M. Badri, G. Symons, E. Pietersen, L. Page-Shipp, A. Burns, P. Baitiswe, M. Grobusch, P. Willcox, A. Zumla, K. Dheda (Cape Town, Johannesburg, Kimberley, South Africa; , United Kingdom)

Source: Annual Congress 2010 - Multidrug-resistant and extensively drug-resistant tuberculosis
Session: Multidrug-resistant and extensively drug-resistant tuberculosis
Session type: Oral Presentation
Number: 353
Disease area: Respiratory infections

Congress or journal article abstractSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Shean, M. Badri, G. Symons, E. Pietersen, L. Page-Shipp, A. Burns, P. Baitiswe, M. Grobusch, P. Willcox, A. Zumla, K. Dheda (Cape Town, Johannesburg, Kimberley, South Africa; , United Kingdom). Adverse drug reactions in South African patients being treated for XDR-TB. Eur Respir J 2010; 36: Suppl. 54, 353

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Death rates in patients during and after MDR-TB treatment in a semi rural area of South Africa
Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Year: 2011

Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea
Source: Eur Respir J, 54 (5) 1900811; 10.1183/13993003.00811-2019
Year: 2019



Adverse effects of treatment in HIV-associated tuberculosis patients in Iran
Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts
Year: 2011


Adverse drug reactions to second line anti tuberculosis drugs: A prospective study in Mumbai, India
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013

XDR-TB in South Africa: from clinical management to public-health action
Source: Annual Congress 2011 - PG12 TB-PAN-NET Multidrug-resistant and extensively drug-resistant tuberculosis: update on clinical management
Year: 2011


A follow up Study of TB patients put on DOTS from South India
Source: International Congress 2017 – Clinical challenges in chronic lung diseases
Year: 2017


Adverse effects of MDR-TB treatment with a standardized regimen: A report from Iran
Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities
Year: 2010


The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?
Source: Eur Respir J, 50 (2) 1700753; 10.1183/13993003.00753-2017
Year: 2017



Primary drug resistance in HIV/tuberculosis patients in two large cities of Siberia
Source: International Congress 2016 – Non-tuberculous mycobacteria: HIV-TB co-infection and adenosine deaminase (ADA)
Year: 2016

Treatment outcomes for multidrug-resistant tuberculosis (MDR-TB) patients in Africa
Source: Annual Congress 2011 - Multidrug-resistant tuberculosis
Year: 2011

The incidence of adverse reactions in anti-tuberculosis chemotherapy in S-W Romania
Source: Annual Congress 2011 - Clinical challenges in tuberculosis
Year: 2011


Prognosis and outcome in patients with extremely drug resistant tuberculosis from the Western Cape province, South Africa
Source: Annual Congress 2008 - Outcomes of tuberculosis treatment
Year: 2008

Culture conversion rates of multi-drug resistant (MDR-TB) patients treated in the community versus an inpatient setting in a rural area of the Western Cape (WC) of South Africa
Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment
Year: 2012



Adverse events in patients with MDR TB, treated by three types of the chemotherapy regimens
Source: International Congress 2019 – Tuberculosis: treatment and management
Year: 2019

Adverse effects among MDR/XDR TB patients with viral hepatitus appearing during TB chemotherapy
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020


Spectrum of adverse drug reactions during MDR TB treatment
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013

Smoking and treatments among asthma patients in South Korea
Source: Annual Congress 2011 - Smoking-related diseases and smoking cessation
Year: 2011

Adverse reaction of TB treatment with 2nd line drugs in a tuberculosis TB dispensary
Source: Eur Respir J 2004; 24: Suppl. 48, 648s
Year: 2004

Adverse reactions to bupropion: fourteen cases reported in a French regional pharmacovigilance center. Impact on smoking withdrawal
Source: Eur Respir J 2005; 26: Suppl. 49, 155s
Year: 2005

Drug resistance and HIV rates are high in Eastern European patients with Tuberculosis in a South East London Hospital
Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Year: 2019